Home・Aandelen Lijst・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Open

SectorGezondheidszorg

14.93 2.47

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

14.47

Max

14.8

Belangrijke statistieken
By Trading Economics
Inkomsten	-176M 34M
Verkoop	591K 78M
K/W Sectorgemiddelde	7.112 64.641
EPS	0.25
Winstmarge	44.212
Werknemers	128
EBITDA	2.7M 50M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+7.55% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-92M 2B
Vorige openingsprijs	12.46
Vorige sluitingsprijs	14.93

Nieuwssentiment

By Acuity

50%

151 / 340 Rangschikking in Healthcare

Aurinia Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 aug 2026, 22:01 UTC

Aurinia Pharmaceuticals shares are higher in after-market hours, despite being below the 20-day moving average and three prior lower daily closes.

1 aug 2026, 00:01 UTC

Aurinia Pharmaceuticals Inc is trading lower in after-market hours, reflecting a significant decline in the overall market and ongoing weakness in performance metrics.

31 jul 2026, 21:01 UTC

Aurinia Pharmaceuticals Inc is higher in after-market trading, rising notably from a flat start. The stock remains below its 20-day moving average.

30 jul 2026, 20:31 UTC

Aurinia Pharmaceuticals Inc. shares rose in after-market trading, following a broader market trend as the S&P 500 also gained. No specific news was identified.

29 jul 2026, 22:01 UTC

Aurinia Pharmaceuticals Inc shares are lower in after-market hours, showing notable weakness and trading below its 20-day moving average. No specific news was identified.

28 jul 2026, 19:36 UTC

Aurinia Pharmaceuticals shares are lower, reflecting volatility amid broader market conditions. The stock is trading significantly below its 20-day moving average.

27 jul 2026, 19:16 UTC

Aurinia Pharmaceuticals is trading higher, benefiting from lower oil prices and easing inflation concerns ahead of the Federal Reserve meeting later this week.

24 jul 2026, 18:26 UTC

Aurinia Pharmaceuticals is trading higher, despite pulling back from earlier gains. Broader market volatility, influenced by declining oil prices, impacts sentiment.

22 jul 2026, 19:46 UTC

Aurinia Pharmaceuticals shares are lower today, continuing a decline since Tuesday's close. The stock is near its one-month trading range's lower end.

21 jul 2026, 19:16 UTC

Aurinia Pharmaceuticals is higher today, supported by a broader market uptick as investor interest in AI-related stocks grows ahead of major tech earnings.

20 jul 2026, 20:01 UTC

Aurinia Pharmaceuticals is lower today, reflecting broader market declines amid geopolitical tensions and oil price fluctuations. The stock hit a session low earlier.

Peer Vergelijking

Prijswijziging

Aurinia Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

7.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.67 USD 7.55%

Hoogste 17 USD

Laagste 15 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aurinia Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Gebaseerd op 3 analisten die aandelenratings hebben gegeven aan Aurinia Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

151 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.